Table 3.
Analogs exploring modification of the tether or piperazine core.
Compound ID | Structure | D3R agonist activity1 | D2R agonist activity1 | D2R antagonist activity1 | |||
---|---|---|---|---|---|---|---|
EC50 (nM) | Emax (% control) | EC50 (nM) | Emax (% control) | IC50 (nM) | Imax (% control) | ||
46 | ![]() |
9,300 ± 2,500 | 106 ± 11 | Inactive | Inactive | >100,000 | ND |
47 | ![]() |
160 ± 33 | 86 ± 7 | Inactive | Inactive | 18,000 ± 2,900 | 89 ± 7 |
48 | ![]() |
4,400 ± 2,300 | 55 ± 7 | Inactive | Inactive | >100,000 | ND |
49 | ![]() |
510 ± 110 | 101 ± 7 | 4,200 ± 900 | 29 ± 1 | >100,000 | ND |
50 | ![]() |
Inactive | Inactive | Inactive | Inactive | Inactive | Inactive |
51 | ![]() |
Inactive | Inactive | Inactive | Inactive | 18,000 ± 4,800 | 72 ± 4.6 |
β-arrestin recruitment activity was assessed as described in Figure 2. Emax values are expressed as a percentage of the maximum dopamine response observed in the same assay. Imax values are expressed as a percentage of the maximum inhibition of a dopamine (EC80 concentration) response observed with the antagonist sulpiride in the same assay.
ND Curve did not plateau.